Top Markets
Coin of the day
Perseus Proteomics Inc. Perseus Proteomics Inc.

Perseus Proteomics Inc.

4882
株式のランク #30348
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology... Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
株価
$0.93298493
時価総額
$17.19M
変化(1日)
-1.38%
変化(1年)
-62.47%
JP
取引 Perseus Proteomics Inc. (4882)

カテゴリー

Perseus Proteomics Inc.(4882)の利益
2026 時点の利益 TTM: 0
Perseus Proteomics Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Perseus Proteomics Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$33.59B -
US
$25.20B -
US
$8.70B -
US
$21.39B -
CH
$5.95B -
US